conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance, and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
------------------------------------------------REFEREE COMMENTS
Referee #1
The Golgi apparatus undergoes fragmentation during G2/M phase and reassembles during mitotic exit. It has been reported that the fragmentation requires three kinases: cyclin-dependent kinase 1 (Cdk1), polo-like kinase (Plk) and MAPK/ERK kinase 1 (MEK1), and that the reassembly requires an ER-Golgi membrane-localized kinase Myt1. Myt1 is known to be a direct downstream target of Plk or p90 ribosomal S6 kinase (RSK) in Xenopus embryonic/meiotic cell cycle, and RSK is established as a direct downstream target of the MEK1-ERK pathway. However, there is no study addressing the relationship between MEK1 and Myt1 in mitotic Golgi fragmentation. Myt1 knockdown by siRNA accelerated M phase entry in HeLa cells (Figure 1 ). Although Myt1 knockdown did not affect the morphology or secretory function of Golgi apparatus in interphase cells (Figure 2 ), it enhanced mitotic cytosol-induced fragmentation of Golgi in permeabilized interphase cells (Figures 3, 4A and 4B) . The mitotic cytosol-induced Golgi fragmentation was reduced by overexpression of wild-type Myt1, treatment with a MEK1 inhibitor PD98059 or immunodepletion of Plk1, but not by treatment with a RSK inhibitor or a Cdk1 inhibitor (Figures 4C, 5A, 6A and 6B) . The PD98059-induced reduction in Golgi fragmentation, but not the Plk1 immunodepletion-induced reduction, was cancelled by Myt1 knockdown (Figures 5B and 6C) . Moreover, PD98059 treatment or siRNA-mediated MEK1 knockdown delayed M phase entry, and this delay was cancelled by Myt1 knockdown (Figure 7 ). Also, Myt1 phosphorylation during M phase was affected by PD98059 treatment or siRNA-mediated MEK1 knockdown (Figure 8 ). These results suggest that MEK1, but not Plk1, RSK or Cdk1, inhibits Myt1 to regulate mitotic Golgi fragmentation. In vitro kinase assay showed that MEK1 does not directly phosphorylate Myt1 (Figure 9 ). This study thus demonstrates that MEK1 induces Golgi fragmentation through an unknown mechanism involving Myt1 inhibition.
The data presented are solid. This study suggests a novel molecular mechanism that links MEK1 to Myt1, although the details of the mechanism are still unresolved. I recommend publication of this manuscript in EMBO J., if the following points are properly addressed.
1) The authors should address the mechanisms of MEK1-induced inhibition of Myt1 in more detail. The authors only show that MEK1 does not phosphorylate Myt1 in vitro. This result alone, however, is not enough to define the mechanisms.
2) The authors should address whether MEK1-mediated Myt1 inhibition is important for Golgi fragmentation in non-permeabilized cells.
Referee #2
This paper provides evidence for the implication of the membrane-bound kinase Myt1 in Golgi membrane fragmentation. Downregulation of Myt1 by siRNAs does not affect Golgi organization or protein secretion in interphase HeLa cells but potentiates Golgi fragmentation induced by mitotic cytosol in permeabilized cells. Moreover, Myt1 downregulation rescues both impaired Golgi membrane fragmentation and delayed mitosis entry produced by the inhibition or the knockdown of MEK1, suggesting that Myt1 functions downstream of MEK1. Further experiments show that inhibitors of Rsk, Plk or Cdk1, three kinases that have been previously reported to phosphorylate Myt1, do not affect Golgi membrane fragmentation induced by mitotic cytosol in permeabilized HeLa cells. The authors propose that Myt1 inhibition by MEK1 is required for mitotic Golgi fragmentation. This is an interesting story, the manuscript is well written and the conclusions are supported by good quality results. The authors also provide rational explanations for the apparent discrepancies with work published by others on the implication of MEK1 and Myt1 in the regulation of Golgi membrane dynamics.
Specific points:
1. The proposal that Myt1 regulation by MEK1 is not mediated by the downstream kinase Rsk is intriguing. Especially considering that Rsk inhibition does impair mitotic Myt1 phosphorylation in Nocodazole-treated HeLa cells, apparently as efficiently as MEK1 inhibition (Fig 8E) . These conclusions are based on the use of a single chemical inhibitor, whose effectiveness in the assay conditions is not demonstrated. It would be important to confirm the differential requirement for MEK1 but not Rsk in Golgi membrane fragmentation using at least one more inhibitor of each.
2. The authors could find no evidence for the direct phosphorylation of Myt1 by MEK1. However, Myt1 regulation could be mediated by MEK1-activated ERK1 or ERK2, and the authors have all tools in hand to test this possibility, just adding Myt1 to the kinase assays of Fig 9A . If Myt1 is phoshorylated by ERK1/2, the next step would be to analyze how siRNA-mediated downregulation of ERK1/2 affects Golgi membrane fragmentation. These experiments should be rather straightforward to perform and potentially very informative.
3. Since all the work reported here is based on HeLa cells, maybe authors should also comment on whether cell-type specific differences could account for some of the discrepancies with other papers.
4. Would be Myt1 required for the MEK1-induced phosphorylation of GRASP55?
5. It seems likely that Myt1 donwregulation would increase Cdk1 activity, which in turn could contribute to the enhanced Golgi fragmentation observed. This should be discussed.
Referee #3
The article investigates a novel angle of MEK1 activity in Golgi fragmentation at the onset of mitosis. There has been a debate in the field on which of MEK1 or CDK1 was involved in Golgi fragmentation. This issue was previously addressed by Kano (2000) (curiously not referenced in this paper). The Kano's group showed that the first disassembly step (Golgi ribbon unlinking and release of the Golgi stacks) was MEK1 dependent whereas the following vesiculation of the Golgi stacks was CDK1 dependent. Furthermore, the Golgi ribbon unlinking at G2 has been shown to act as a G2/M checkpoint. If it does not happen properly, the cell entry into mitosis inhibited or delayed.
Here the authors show that MEK1 modulates Myt1 activity with an impact on Golgi fragmentation and cell cycle progression. The authors use a combination of cell cycle synchronization using double thymidine block (S phase) and nocodazole treatment (metaphase) combined with depletion by siRNAs, an assay based on semi-intact HeLa cells incubated with interphase and mitotic cytosols supplemented with several inhibitors and reconstitution assay with purified or IPed proteins and membrane.
The paper essentially contains 4 conceptual parts: A) They show an inhibitory role for Myt1 on mitotic Golgi fragmentation using their semi intact cell assay. -Myt1 depletion or kinase-dead Myt1 transfection accelerates Golgi fragmentation in semi intact cell assay incubated with mitotic cytosol (not interphase).
-Overexpression of Myt1 prevents Golgi fragmentation. B) Myt 1 is controlled by MEK1 activity -Inhibition of MEK1 by PD prevents Golgi fragmentation in WT semi intact HeLa cells, but when cells are depleted of Myt1, PD has no effect and the fragmentation occurs very efficiently. C) Myt1 is phosphorylated in mitosis (peak at 10h release of thymidine block) and this does not depend on Rsk or Plk or CDK1, but does depend on MEK1 (inhibited and delayed by PD). However, using an in vitro phosphorylation assay with purified Golgi membrane or purified/IPed proteins, the authors cannot show a direct phosphorylation of Myt1 by MEK1 in mitosis.
The authors propose that during mitosis, MEK1 leads to phosphorylation (via an unknown kinase) of Myt1 that becomes inactivated. This alleviates its inhibitory role on the mitotic Golgi fragmentation that becomes more efficient.
D) The 4th part of the manuscript aims to illustrate the role of the signaling branch MEK1/Myt1 in cell cycle progression. In doing this, the authors test again the notion that Golgi fragmentation is a checkpoint for cell entry into mitosis. To do so, the authors use cell synchronization protocol (double thymidine block) to show that: -Myt1 depletion accelerates cell entry to mitosis by 2 hours. -MEK1 and Myt1 interact genetically for the control of the cell cycle and that MEK1 is upstream of Myt1.
Taking all these results together, the authors propose that MEK1 activity leads to Myt1 inhibition. As Myt1 is a Golgi fragmentation inhibitor, MEK1 activity allows Golgi fragmentation and cells can enter into mitosis.
The article is interesting and undoubtedly represents a large amount of work that is reflected by its density. This is not helped by the quick writing style and brushing over details and explanation. Furthermore, there are a number of concerns that need to be addressed. 1) Conceptually, I am confused about the timing of Myt1 phosphorylation. It peaks 10h after release from the Thy block ( Figure 1B) . The cells are then in mitosis, way passed the possible Golgi checkpoint at G2. This is confirmed by Figure 1A and 8A where Myt1 is phosphorylated only in mitotic cells. To have role in controlling cell entry into mitosis via Golgi fragmentation, I would have expected to see Myt1 phosphorylation from 2-6h post release (G2 duration).
MEK1 is involved in this phosphorylation at mitosis. Myt1 is inhibited by PD (MEK1 inhibitor) only in mitosis (Figure 8 , Noc treated cells). However, this inhibition by PD is in fact a delay of 2h, so Myt1 is still phosphorylated but later. I do not understand the relevance of inhibiting/delaying an inhibitor of Golgi fragmentation (Myt1 phosphorylation) once the Golgi is already fragmented. Can this be explained?
2) This suggests that the effect of MEK1 on Myt1 may control Golgi fragmentation (stack vesiculation at prophase/metaphase) but perhaps not the Golgi unlinking occurring at G2, the step that has very carefully been shown to be the one controlling cell entry to mitosis. Does MEk1/Myt1 operate at mitosis? Yet, it also seems to operate at the earliest stage of Golgi fragmentation and cell cycle progression (as shown by many and stated in the abstract). Can MEK1 have two roles at two different stage of cell cycle. This needs to be addressed. In this regard, the authors write that Myt1 inactivation is necessary for CDK1 activation and this has been shown to drive Golgi stack fragmentation and of course cell cycle progression. Could there be a role of MEK1 on activating CDK1 via Myt1 phosphorylation? Can this be tested? The authors do not favor this hypothesis because Golgi fragmentation in their semi intact cell assay is not inhibited by olomucine (CDK1 inhibitor) but I think that what happens to Myt1 in mitosis is not entirely recapitulated by this assay. Can activation of CDK1 monitored under conditions of MEK1 inhibition?
3) Related to point 2, I do not understand how PD or MEK1 depletion can delay the Myt1 phosphorylation (by 2h). This suggests another phosphorylation event that is MEK1 independent. Is it also inhibitory for Golgi fragmentation? Is it related to CDK1 activation?
4) The role of Myt1 in Golgi fragmentation is shown using the semi intact cell assay incubated with mitotic cytosol whereas its role in cell cycle progression is done with cells release from a thymidine block. At best, this is an interesting correlation, which could have been remedied by studying the state of the Golgi in cells released from the block. These cells were stained with Dapi and PhosphoH3 antibody. They could have been stained by an anti Golgi antibody. Or HeLa cells expressing ManII-GFP could have been used for these synchronization experiments. This experiment should be performed to justify the title.
5) Related to point 1 (Figure1 and 7) , not only the mitotic index should be scored but also the number of cells in G2.
6) How is the RNAi is performed in the cell synchronization experiments? If I understand the text (there is no description in MM or legends for figure) , the cells are first synchronized using the double thymidine block protocol and then transfected with relevant siRNA. So at best, they are depleted for 18h+12h post release. This is considerably shorted than the 48-72h depletion time ( Figure 1D and 7A) where cells are simply transfected by siRNAs. These WB show that the oligos CAN deplete Myt1 and MEK1 efficiently, not that they DO so after 24h when transfected in thymidine blocked cells. Referee #1
The Golgi apparatus undergoes fragmentation during G2/M phase and reassembles during mitotic exit. It has been reported that the fragmentation requires three kinases: cyclin-dependent kinase 1 (Cdk1), polo-like kinase (Plk) and MAPK/ERK kinase 1 (MEK1), and that the reassembly requires an ER-Golgi membrane-localized kinase Myt1. Myt1 is known to be a direct downstream target of Plk or p90 ribosomal S6 kinase (RSK) in Xenopus embryonic/meiotic cell cycle, and RSK is established as a direct downstream target of the MEK1-ERK pathway. However, there is no study addressing the relationship between MEK1 and Myt1 in mitotic Golgi fragmentation. Myt1 knockdown by siRNA accelerated M phase entry in HeLa cells (Figure 1 ). Although Myt1 knockdown did not affect the morphology or secretory function of Golgi apparatus in interphase cells (Figure 2) , it enhanced mitotic cytosol-induced fragmentation of Golgi in permeabilized interphase cells (Figures 3, 4A and 4B) . The mitotic cytosol-induced Golgi fragmentation was reduced by overexpression of wild-type Myt1, treatment with a MEK1 inhibitor PD98059 or immunodepletion of Plk1, but not by treatment with a RSK inhibitor or a Cdk1 inhibitor (Figures 4C, 5A, 6A and 6B). The PD98059-induced reduction in Golgi fragmentation, but not the Plk1 immunodepletion-induced reduction, was cancelled by Myt1 knockdown ( Figures 5B and 6C ). Moreover, PD98059 treatment or siRNA-mediated MEK1 knockdown delayed M phase entry, and this delay was cancelled by Myt1 knockdown (Figure 7) . Also, Myt1 phosphorylation during M phase was affected by PD98059 treatment or siRNAmediated MEK1 knockdown (Figure 8 ). These results suggest that MEK1, but not Plk1, RSK or Cdk1, inhibits Myt1 to regulate mitotic Golgi fragmentation. In vitro kinase assay showed that MEK1 does not directly phosphorylate Myt1 (Figure 9 ). This study thus demonstrates that MEK1 induces Golgi fragmentation through an unknown mechanism involving Myt1 inhibition.
1) The authors should address the mechanisms of MEK1-induced inhibition of Myt1 in more detail. This is an interesting story, the manuscript is well written and the conclusions are supported by good quality results. The authors also provide rational explanations for the apparent discrepancies with work published by others on the implication of MEK1 and Myt1 in the regulation of Golgi membrane dynamics. Figure S1 . These chemicals were then tested for their effects on Golgi fragmentation in permeabilized cells. Only UO126 inhibited mitotic cytosol dependent Golgi membrane fragmentation, which confirms the requirement for MEK1 but not RSK and CDK1 in Golgi membrane fragmentation ( Figure S2 ).
2. The authors could find no evidence for the direct phosphorylation of Myt1 by MEK1. However, Myt1 regulation could be mediated by MEK1-activated ERK1 or ERK2, and the authors have all tools in hand to test this possibility, just adding Myt1 to the kinase assays of Fig 9A. If Myt1 is phoshorylated by ERK1/2, the next step would be to analyze how siRNA-mediated downregulation of ERK1/2 affects Golgi membrane fragmentation. These experiments should be rather straightforward to perform and potentially very informative.
We have performed the experiment suggested by the reviewer. Myt1 KD was incubated with purified mitotic MEK1 and pure ERK2 with 32P-ATP. MEK1 phosphorylated ERK2, however, Myt1 was not phosphorylated under these conditions (Figure S3). This corroborates our proposal that MEK1 does not directly phosphorylates Myt1. Additionally, Myt1 phosphorylation by MEK1 is not via its known substrate ERK2.
We briefly describe this possibility in the discussion

Would be Myt1 required for the MEK1-induced phosphorylation of GRASP55?
We tested this experimentally. GRASP55 was immunoprecipitated from HeLa cells synchronized in S-phase (thymidine-treated cells) or mitosis (nocodazole-treated cells). Then, using the mitotic phosphoprotein monoclonal-2 (MPM-2) antibody, which recognizes a phosphorylated S/T-P epitope, we tested the MPM-2 reactivity of GRASP55 as reported earlier by Linstedt and colleagues (Jesch et al, 2001). As shown in Figure S4A, GRASP55 immunoprecipitated from mitotic synchronized cells was strongly MPM-2 reactive, in contrast to GRASP55 immunoprecipitated from S-phase synchronized cells. The inhibition of MEK1 with PD reduces the phosphorylation of GRASP55 in mitotic cells as revealed by the decrease of MPM-2 reactivity (Figure S4A). In order to determine whether Myt1 activity is required for the mitotic GRASP55 phosphorylation mediated by MEK1, HeLa cells were transfected with control or Myt1 specific siRNA oligos and synchronized in mitosis by nocodazole treatment in the presence or absence of PD. The downregulation of Myt1 did not affect the MPM-2 reactivity of GRASP55 immunoprecipitated from mitotic cells (Figure S4B), suggesting that MEK1-mediated GRASP55 phosphorylation in mitotic cells does not require Myt1.
5. It seems likely that Myt1 donwregulation would increase CDK1 activity, which in turn could contribute to the enhanced Golgi fragmentation observed. This should be discussed.
CDK1 is a well-known substrate of Myt1 and it has been reported that CDK1 is required for the fragmentation of isolated Golgi stacks in small tubules and vesicles. Using a Golgi fragmentation assay in permeabilized cell incubated with mitotic cytosol, as previously reported (Acharya et al, 1998) and confirmed in this study, inhibition of CDK1 with olomoucine and RO-3306 did not affect Golgi membrane fragmentation. But we cannot rule out the possibility that an increase in CDK1 activity upon Myt1 downregulation affect fragmentation of the Golgi stacks post MEK1 dependent reaction. This is mentioned in the discussion.
Referee #3
We apologize for this mistake. The reference is now included in the introduction
The paper essentially contains 4 conceptual parts: A) They show an inhibitory role for Myt1 on mitotic Golgi fragmentation using their semi intact cell assay.
-Myt1 depletion or kinase-dead Myt1 transfection accelerates Golgi fragmentation in semi intact cell assay incubated with mitotic cytosol (not interphase).
-Overexpression of Myt1 prevents Golgi fragmentation.
B) Myt 1 is controlled by MEK1 activity -Inhibition of MEK1 by PD prevents Golgi fragmentation in WT semi intact HeLa cells, but when cells are depleted of Myt1, PD has no effect and the fragmentation occurs very efficiently.
C) Myt1 is phosphorylated in mitosis (peak at 10h release of thymidine block) and this does not depend on Rsk or Plk or CDK1, but does depend on MEK1 (inhibited and delayed by PD). However, using an in vitro phosphorylation assay with purified Golgi membrane or purified/IPed proteins, the authors cannot show a direct phosphorylation of Myt1 by MEK1 in mitosis.
The article is interesting and undoubtedly represents a large amount of work that is reflected by its density. This is not helped by the quick writing style and brushing over details and explanation. Furthermore, there are a number of concerns that need to be addressed.
1) Conceptually, I am confused about the timing of Myt1 phosphorylation. It peaks 10h after release from the Thy block ( Figure 1B) . The cells are then in mitosis, way passed the possible Golgi checkpoint at G2. This is confirmed by Figure 1A and 8A where Myt1 is phosphorylated only in mitotic cells. To have role in controlling cell entry into mitosis via Golgi fragmentation, I would have expected to see Myt1 phosphorylation from 2-6h post release (G2 duration).
During the progression into the mitosis, Myt1 phosphorylation peaks 10 h after release from the double thymidine block. However, as illustrated Figure 1C and 2) This suggests that the effect of MEK1 on Myt1 may control Golgi fragmentation (stack vesiculation at prophase/metaphase) but perhaps not the Golgi unlinking occurring at G2, the step that has very carefully been shown to be the one controlling cell entry to mitosis. Does MEk1/Myt1 operate at mitosis? Yet, it also seems to operate at the earliest stage of Golgi fragmentation and cell cycle progression (as shown by many and stated in the abstract). Can MEK1 have two roles at two different stage of cell cycle. This needs to be addressed. In this regard, the authors write that Myt1 inactivation is necessary for CDK1 activation and this has been shown to drive Golgi stack fragmentation and of course cell cycle progression.
Could there be a role of MEK1 on activating CDK1 via Myt1 phosphorylation? Can this be tested?
The authors do not favor this hypothesis because Golgi fragmentation in their semi intact cell assay is not inhibited by olomucine (CDK1 inhibitor) but I think that what happens to Myt1 in mitosis is not entirely recapitulated by this assay. (Colanzi et al, 2007) had a fragmented Golgi apparatus ( Figure 2D ) Figure 6C ).
. Down regulation of Myt1 increases the percentage of cells with fragmented Golgi to 80% (Figure 2D). In these experimental conditions, the inhibition of MEK1 with PD in control siRNA transfected cells decreases the percentage of cells with fragmented Golgi to 40%, however as demonstrated in permeabilized cells, the knockdown of Myt1 alleviates the function of MEK1 in the Golgi fragmentation process with a percentage of cell with fragmented Golgi to 80% (
In order to score the number of cells in G2 for the Figure 1 and Figure 7E and 7H. Figure  7E , the analysis of cells in G2 showed that in PD treated cells, the kinetic of transition from G2 to M-phase was delayed compared with DMSO treated cells. Figure 7H , knockdown of Myt1 alleviated the G2/M-phase transition delay induced by PD treatment.
6) How is the RNAi is performed in the cell synchronization experiments? If I understand the text (there is no description in MM or legends for figure) , the cells are first synchronized using the double thymidine block protocol and then transfected with relevant siRNA. So at best, they are depleted for 18h+12h post release. This is considerably shorted than the 48-72h depletion time ( Figure 1D and 7A Figure 1D , 5A and and 7A, the depletion efficiency has been scored as shown in Figure 1E , 9) I find that the part of Plk (end page 11 and page 12, Figure 6 ) should be placed earlier, just after Colanzi et al, 2000, (4th line page 11). Otherwise, the argument of the link between MEK1 and Myt1 is split and does not flow. Thank you for submitting your revised manuscript to the EMBO journal. Your study has now been seen referee #3 and the comments are provided below. As you can see, the referee appreciates the introduced changes, but also suggests a number of important text changes. I would like to ask you address these remaining issues in a final round of revision.
Thank you for submitting your interesting manuscript to the EMBO Journal.
Yours sincerely,
Editor
